These inverse findings imply that we may expect an increased prevalence of HER2 expression in Tanzania and sub-Saharan Africa in general when breast cancer immunostaining becomes routine because of the prevalent hormonal receptor negativity. The gene discussed is NR4A1; the disease is breast cancer.